Lyra Therapeutics (LYRA) Stock Forecast, Price Target & Predictions
LYRA Stock Forecast
Lyra Therapeutics stock forecast is as follows: an average price target of $0.50 (represents a 93.12% upside from LYRA’s last price of $0.26) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
LYRA Price Target
The average price target for Lyra Therapeutics (LYRA) is $0.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $0.50 to $0.50. This represents a potential 93.12% upside from LYRA's last price of $0.26.
LYRA Analyst Ratings
According to 5 Wall Street analysts, Lyra Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for LYRA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lyra Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 07, 2024 | Dennis Ding | Jefferies | $0.50 | $0.52 | -4.12% | 93.12% |
The latest Lyra Therapeutics stock forecast, released on May 07, 2024 by Dennis Ding from Jefferies, set a price target of $0.50, which represents a -4.12% decrease from the stock price at the time of the forecast ($0.52), and a 93.12% increase from LYRA last price ($0.26).
Lyra Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $0.50 |
| Last Closing Price | $0.26 | $0.26 | $0.26 |
| Upside/Downside | -100.00% | -100.00% | 93.12% |
In the current month, the average price target of Lyra Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lyra Therapeutics's last price of $0.26. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 20, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 20, 2024 | Jefferies | Buy | Buy | Hold |
| May 07, 2024 | Jefferies | Buy | Buy | Hold |
| May 07, 2024 | Jefferies | - | Hold | Downgrade |
| May 06, 2024 | BTIG | Buy | Neutral | Downgrade |
| May 06, 2024 | BTIG | Buy | Reduce | Downgrade |
| May 06, 2024 | William Blair | - | Market Perform | Downgrade |
| May 02, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Feb 07, 2023 | BTIG | Buy | Buy | Hold |
Lyra Therapeutics's last stock rating was published by H.C. Wainwright on Aug 15, 2024. The company gave LYRA a "Neutral" rating, the same as its previous rate.
Lyra Therapeutics Financial Forecast
Lyra Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $146.00K | $544.00K | $458.00K | $410.00K | $11.00K | $359.00K | $407.00K | $5.37M | $271.00K | $14.00K |
| Avg Forecast | $1.31M | $108.00K | $108.00K | $108.00K | $54.00K | $54.00K | $54.00K | $54.00K | $324.40K | $315.60K | $532.00K | $344.92K | $388.80K | $371.60K | $136.67K | $159.50K | $148.80K | $101.75K | $1.43M | $2.68M | $1.13M | $375.00K |
| High Forecast | $1.31M | $108.00K | $108.00K | $108.00K | $54.00K | $54.00K | $54.00K | $54.00K | $324.40K | $473.40K | $532.00K | $344.96K | $403.75K | $371.60K | $136.67K | $159.50K | $148.80K | $101.75K | $1.43M | $2.68M | $1.13M | $375.00K |
| Low Forecast | $1.31M | $108.00K | $108.00K | $108.00K | $54.00K | $54.00K | $54.00K | $54.00K | $324.40K | $157.80K | $532.00K | $344.88K | $373.85K | $371.60K | $136.67K | $159.50K | $148.80K | $101.75K | $1.43M | $2.68M | $1.13M | $375.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 1.46% | 3.35% | 2.57% | 0.07% | 3.53% | 0.28% | 2.00% | 0.24% | 0.04% |
Lyra Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $344.92K, with a low forecast of $344.88K, and a high forecast of $344.96K. LYRA's average Quarter revenue forecast represents a 136.24% increase compared to the company's last Quarter revenue of $146.00K (Dec 23).
Lyra Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-16.39M | $-16.83M | $-16.50M | $-17.03M | $-13.62M | $-14.55M | $-14.23M | $-6.75M | $-13.36M | $-10.73M |
| Avg Forecast | $-262.90K | $-21.60K | $-21.60K | $-21.60K | $-10.80K | $-10.80K | $-10.80K | $-10.80K | $-64.88K | $-63.12K | $-106.40K | $-68.98K | $-77.76K | $-74.32K | $-27.33K | $-31.90K | $-29.76K | $-20.35K | $-286.95K | $-8.50M | $-225.00K | $-75.00K |
| High Forecast | $-262.90K | $-21.60K | $-21.60K | $-21.60K | $-10.80K | $-10.80K | $-10.80K | $-10.80K | $-64.88K | $-31.56K | $-106.40K | $-68.97K | $-74.77K | $-74.32K | $-27.33K | $-31.90K | $-29.76K | $-20.35K | $-286.95K | $-6.80M | $-225.00K | $-75.00K |
| Low Forecast | $-262.90K | $-21.60K | $-21.60K | $-21.60K | $-10.80K | $-10.80K | $-10.80K | $-10.80K | $-64.88K | $-94.68K | $-106.40K | $-68.99K | $-80.75K | $-74.32K | $-27.33K | $-31.90K | $-29.76K | $-20.35K | $-286.95K | $-10.21M | $-225.00K | $-75.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 210.81% | 226.42% | 603.78% | 533.84% | 457.58% | 714.88% | 49.60% | 0.79% | 59.38% | 143.08% |
undefined analysts predict LYRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lyra Therapeutics's previous annual EBITDA (undefined) of $NaN.
Lyra Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-15.16M | $-15.65M | $-15.62M | $-16.25M | $-14.23M | $-14.71M | $-14.42M | $-7.00M | $-13.34M | $-11.05M |
| Avg Forecast | $-17.93M | $-14.49M | $-10.00M | $-7.97M | $-8.84M | $-10.15M | $-10.80M | $-12.11M | $-12.60M | $-14.07M | $-21.88M | $-17.16M | $-20.62M | $-20.78M | $-27.71M | $-23.89M | $-27.10M | $-28.80M | $-24.41M | $-8.88M | $-51.66M | $-48.17M |
| High Forecast | $-17.93M | $-14.49M | $-10.00M | $-7.97M | $-8.84M | $-10.15M | $-10.80M | $-12.11M | $-12.60M | $-11.63M | $-21.88M | $-17.16M | $-15.00M | $-20.78M | $-27.71M | $-23.89M | $-27.10M | $-28.80M | $-24.41M | $-7.10M | $-51.66M | $-48.17M |
| Low Forecast | $-17.93M | $-14.49M | $-10.00M | $-7.97M | $-8.84M | $-10.15M | $-10.80M | $-12.11M | $-12.60M | $-15.91M | $-21.88M | $-17.16M | $-26.87M | $-20.78M | $-27.71M | $-23.89M | $-27.10M | $-28.80M | $-24.41M | $-10.65M | $-51.66M | $-48.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.74% | 0.75% | 0.56% | 0.68% | 0.53% | 0.51% | 0.59% | 0.79% | 0.26% | 0.23% |
Lyra Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LYRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lyra Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $4.36M | $5.00M | $4.57M | $5.13M | $4.40M | $5.14M | $4.13M | $3.89M | $3.57M | $4.02M |
| Avg Forecast | $20.23M | $1.66M | $1.66M | $1.66M | $831.14K | $831.14K | $831.14K | $831.14K | $4.99M | $4.86M | $8.19M | $5.31M | $5.98M | $5.72M | $2.10M | $2.45M | $2.29M | $1.57M | $22.08M | $41.30M | $17.32M | $5.77M |
| High Forecast | $20.23M | $1.66M | $1.66M | $1.66M | $831.14K | $831.14K | $831.14K | $831.14K | $4.99M | $7.29M | $8.19M | $5.31M | $6.21M | $5.72M | $2.10M | $2.45M | $2.29M | $1.57M | $22.08M | $41.30M | $17.32M | $5.77M |
| Low Forecast | $20.23M | $1.66M | $1.66M | $1.66M | $831.14K | $831.14K | $831.14K | $831.14K | $4.99M | $2.43M | $8.19M | $5.31M | $5.75M | $5.72M | $2.10M | $2.45M | $2.29M | $1.57M | $22.08M | $41.30M | $17.32M | $5.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.87% | 2.17% | 2.09% | 1.92% | 3.28% | 0.19% | 0.09% | 0.21% | 0.70% |
Lyra Therapeutics's average Quarter SG&A projection for Mar 24 is $5.31M, based on 1 Wall Street analysts, with a range of $5.31M to $5.31M. The forecast indicates a 21.85% rise compared to LYRA last annual SG&A of $4.36M (Dec 23).
Lyra Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.27 | $-0.00 | $-0.44 | $-0.47 | $-0.40 | $-0.42 | $-0.54 | $-1.03 | $-0.85 |
| Avg Forecast | $-0.27 | $-0.22 | $-0.15 | $-0.12 | $-0.14 | $-0.15 | $-0.17 | $-0.18 | $-0.19 | $-0.21 | $-0.33 | $-0.26 | $-0.32 | $-0.32 | $-0.42 | $-0.36 | $-0.41 | $-0.44 | $-0.37 | $-0.06 | $-0.79 | $-0.74 |
| High Forecast | $-0.27 | $-0.22 | $-0.15 | $-0.12 | $-0.14 | $-0.15 | $-0.17 | $-0.18 | $-0.19 | $-0.18 | $-0.33 | $-0.26 | $-0.23 | $-0.32 | $-0.42 | $-0.36 | $-0.41 | $-0.44 | $-0.37 | $-0.06 | $-0.79 | $-0.74 |
| Low Forecast | $-0.27 | $-0.22 | $-0.15 | $-0.12 | $-0.14 | $-0.15 | $-0.17 | $-0.18 | $-0.19 | $-0.24 | $-0.33 | $-0.26 | $-0.41 | $-0.32 | $-0.42 | $-0.36 | $-0.41 | $-0.44 | $-0.37 | $-0.06 | $-0.79 | $-0.74 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.83% | 0.85% | 0.00% | 1.21% | 1.14% | 0.91% | 1.13% | 9.82% | 1.31% | 1.16% |
According to undefined Wall Street analysts, Lyra Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LYRA previous annual EPS of $NaN (undefined).
Lyra Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
| CTMX | CytomX Therapeutics | $1.05 | $5.77 | 449.52% | Buy |
| NUVB | Nuvation Bio | $2.30 | $6.75 | 193.48% | Buy |
| TIL | Instil Bio | $28.78 | $78.25 | 171.89% | Hold |
| AUTL | Autolus Therapeutics | $3.50 | $9.50 | 171.43% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.65 | $38.80 | 164.85% | Buy |
| NXTC | NextCure | $1.33 | $3.00 | 125.56% | Buy |
| ASMB | Assembly Biosciences | $16.89 | $35.50 | 110.18% | Buy |
| CGEM | Cullinan Oncology | $15.78 | $31.50 | 99.62% | Buy |
| ACHL | Achilles Therapeutics | $1.02 | $2.00 | 96.08% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| BOLT | Bolt Biotherapeutics | $0.66 | $1.00 | 51.52% | Hold |
LYRA Forecast FAQ
Is Lyra Therapeutics a good buy?
No, according to 5 Wall Street analysts, Lyra Therapeutics (LYRA) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of LYRA's total ratings.
What is LYRA's price target?
Lyra Therapeutics (LYRA) average price target is $0.5 with a range of $0.5 to $0.5, implying a 93.12% from its last price of $0.259. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Lyra Therapeutics stock go up soon?
According to Wall Street analysts' prediction for LYRA stock, the company can go up by 93.12% (from the last price of $0.259 to the average price target of $0.5), up by 93.12% based on the highest stock price target, and up by 93.12% based on the lowest stock price target.
Can Lyra Therapeutics stock reach $0?
LYRA's average twelve months analyst stock price target of $0.5 supports the claim that Lyra Therapeutics can reach $0 in the near future.
What are Lyra Therapeutics's analysts' financial forecasts?
Lyra Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $216K (high $216K, low $216K), average EBITDA is $-43.196K (high $-43.196K, low $-43.196K), average net income is $-41.894M (high $-41.894M, low $-41.894M), average SG&A $3.32M (high $3.32M, low $3.32M), and average EPS is $-0.64 (high $-0.64, low $-0.64). LYRA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.64M (high $1.64M, low $1.64M), average EBITDA is $-328K (high $-328K, low $-328K), average net income is $-50.384M (high $-50.384M, low $-50.384M), average SG&A $25.22M (high $25.22M, low $25.22M), and average EPS is $-0.77 (high $-0.77, low $-0.77).
Did the LYRA's actual financial results beat the analysts' financial forecasts?
Based on Lyra Therapeutics's last annual report (Dec 2023), the company's revenue was $1.56M, beating the average analysts forecast of $1.06M by 47.46%. Apple's EBITDA was $-67.12M, beating the average prediction of $-211K by 31663.76%. The company's net income was $-62.68M, missing the average estimation of $-93.002M by -32.60%. Apple's SG&A was $19.06M, beating the average forecast of $16.26M by 17.19%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.421 by -99.91%. In terms of the last quarterly report (Dec 2023), Lyra Therapeutics's revenue was $146K, missing the average analysts' forecast of $388.8K by -62.45%. The company's EBITDA was $-16.392M, beating the average prediction of $-77.759K by 20980.52%. Lyra Therapeutics's net income was $-15.156M, missing the average estimation of $-20.62M by -26.50%. The company's SG&A was $4.36M, missing the average forecast of $5.98M by -27.19%. Lastly, the company's EPS was $-0.26, missing the average prediction of $-0.315 by -17.46%